(Q44461407)

3 December 2017

Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily (English)

1 reference

3 December 2017

1 reference

William C Stewart

1

1 reference

3 December 2017

Jeanette A Stewart

series ordinal

2

1 reference

3 December 2017

Douglas Day

series ordinal

3

1 reference

3 December 2017

Elizabeth D Sharpe

series ordinal

4

1 reference

3 December 2017

1 June 2003

1 reference

3 December 2017

1 reference

3 December 2017

81

1 reference

3 December 2017

3

1 reference

3 December 2017

242-246

1 reference

Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.

3 December 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

"Who's on first?": Considering the options for primary glaucoma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

Brimonidine 0.2% given two or three times daily versus timolol maleate 0.5% in primary open-angle glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

Efficacy and safety of timolol solution once daily vs timolol gel added to latanoprost.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

7 January 2021

Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

7 January 2021

The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

7 January 2021

Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

7 January 2021

Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0420.2003.00065.X

7 January 2021

10.1034/J.1600-0420.2003.00065.X

Identifiers

DOI

1 reference

3 December 2017

1 reference